M&A Deal Summary

Novaremed Acquires Metys Pharmaceuticals

On September 7, 2021, Novaremed acquired life science company Metys Pharmaceuticals

Acquisition Highlights
  • This is Novaremed’s 1st transaction in the Life Science sector.
  • This is Novaremed’s 1st transaction in Switzerland.

M&A Deal Summary
Date 2021-09-07
Target Metys Pharmaceuticals
Sector Life Science
Buyer(s) Novaremed
Deal Type Add-on Acquisition

Target

Metys Pharmaceuticals

Basel, Switzerland
website
Metys Pharmaceuticals is a biopharmaceutical company developing MP-101 to prevent and treat chemotherapy-induced peripheral neuropathy, an uncomfortable and troubling side effect of several important cancer treatments. Metys Pharmaceuticals was founded in 2013 and is based in Basel, Switzerland.

Search 192,510 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Novaremed

Basel, Germany

website

Category Company
Sector Life Science
DESCRIPTION

Novaremed is a privately-held clinical-stage biopharmaceutical company, is innovating chronic pain management through the development of effective and safe treatment options as an alternative to opioids. Its lead product is NRD.E1, an orally active non-opioid small molecule with a novel mechanism of action, has FDA Fast Track Designation and IND-approval to proceed with a Phase 2b clinical trial for the treatment of painful diabetic peripheral neuropathy (PDPN). Novaremed is based in Basel, Switzerland.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (Switzerland) 1 of 1
Year (2021) 1 of 1
Mergr

Product

Company

Legal